Standout Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced soli... 2018 2026 2020 2023 440
  1. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study (2018)
    Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology

Immediate Impact

11 from Science/Nature 74 standout
Sub-graph 1 of 20

Citing Papers

Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
Epigenetic patterns in a complete human genome
2022 StandoutScience
3 intermediate papers

Works of Blythe Thomson being referenced

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2018 Standout

Author Peers

Author Last Decade Papers Cites
Blythe Thomson 530 366 187 584 39 1.7k
Carl Lenarsky 867 182 309 379 53 1.9k
Bodil Strömbeck 875 318 433 754 46 2.0k
C.A. Griffin 615 172 307 790 40 2.1k
A H Ragab 616 642 314 400 43 2.1k
G. Janka‐Schaub 489 728 109 290 30 1.5k
Judith Landman‐Parker 254 314 144 497 44 1.4k
D Hammond 549 673 193 470 48 2.2k
Gitte Kerndrup 1472 595 422 631 71 2.1k
Osborn B. Eden 411 756 122 546 26 1.5k
G. Malcolm Taylor 203 518 136 332 45 1.5k

All Works

Loading papers...

Rankless by CCL
2026